Beijing-Tianjin-Hebei Alliance Releases 2026 Medical Film Centralized Procurement Results: 95 Companies, 2,466 Specifications Selected
The Beijing-Tianjin-Hebei "3+N" Alliance officially announced the centralized procurement results for medical consumables on January 15, 2026. The medical film category selected 95 winning companies, including AGFA, FUJIFILM, Konica Minolta, and Carestream Health. The procurement covers two types of China medical dry imaging film products—laser film and thermal film—with a total of 2,466 specifications. Hemostatic materials also had 126 specifications selected.
The Alliance is a cross-regional coalition led by Beijing, Tianjin, and Hebei, joined by multiple other provinces. The Alliance uses volume-based negotiation to achieve cost optimization. This approach has been applied to previous rounds for other consumables. The 2026 procurement standardizes pricing for China medical dry imaging film across regions while maintaining quality and supply reliability.
Medical film is a critical consumable for diagnostic imaging. China's annual consumption exceeds 650 million sheets, with a market size near RMB 6 billion. Although the unit price of china medical thermal dry film is modest, the total volume makes it a significant cost factor. The centralized procurement is expected to drive prices to reasonable levels, directly benefiting patients.
Following the announcement, the Alliance set an implementation timeline. Institutions must finalize quantities from February 12 to March 4, 2026. The system activates on May 23, allowing online purchasing and price adjustments. Full execution of china thermal dry imaging film contracts begins May 30.
All winners must comply with national medical device regulations and quality certifications. The procurement includes ongoing monitoring with random testing. Hospitals may reject non-conforming custom medical thermal dry film. A dynamic price adjustment ensures that if a lower price appears in other provincial procurements, the Alliance price is adjusted downward, guaranteeing competitive pricing for custom medical thermal dry film.
The 2026 procurement marks a significant milestone. The participation of 95 companies demonstrates a healthy competitive supply landscape. The model may inform similar initiatives nationwide, balancing cost containment with supply resilience for custom thermal dry imaging film.
The participation of diverse custom thermal dry imaging film suppliers creates a resilient supply chain across one of China's most important healthcare markets. As regional integration deepens, this procurement model may serve as a template for similar initiatives nationwide, reinforcing the continued clinical relevance of custom thermal dry imaging film in China's evolving healthcare landscape.